Abstract 456P
Background
As mentioned by ESMO guidelines on the management of constipation in advanced cancer, combined opiate/naloxone medications have been shown to reduce the risk of OIC through a range of studies. Oxycodone/naloxone prolonged-release tablets (OXN PR) provide similar efficacy, but an improved bowel function compared with oxycodone prolonged-release tablets (OXY PR). This is the first Chinese study about OXN PR in cancer pain population.
Methods
This multi-center, randomized, double-blind controlled trial compared OXN PR to OXY PR for 4 weeks in adult cancer patients with moderate-to-severe pain and OIC. Primary efficacy endpoints: Bowel Function Index (BFI) and Brief Pain Inventory-Short Form (BPI-SF). Key secondary endpoints: use of laxative (bisacodyl tablets) and rescue analgesia (morphine sulfate), quality of life (EQ-5D) and safety.
Results
232 patients were randomized (117 in the OXN PR group; 115 in the OXY PR group). BPI-SF average pain was comparable after 4 weeks between OXN PR and OXY PR groups. The difference of average BFI at 4 weeks was not statistically significant between the 2 treatment groups (FAP, p=0.482). Compared to baseline, a BFI reduction was seen after 1 week in OXN PR group (13.5 points vs. 8.8 points in OXY PR group; p=0.039). Results of an exploratory post-hoc analysis confirmed these findings, with the BFI difference favoring OXN PR. Laxative use was similar between the 2 groups, but a higher percentage of patients required laxatives in OXY PR group compared to OXN PR group at all visits. Average daily dose and percentage of patients taking rescue analgesia were similar at 4 weeks. EQ-5D assessment showed a minor improvement in the OXN PR group and a decline in OXY PR group (non-significant). Fewer adverse events were reported in the OXN PR group (17.5% vs. 27.0% in the OXY PR group); No treatment-related SAEs were reported with OXN PR group.
Conclusions
In managing moderate-to-severe cancer pain among Chinese patients, OXN PR has demonstrated comparable efficacy to OXY PR. Improvements of bowel function were numerically observed and statistically confirmed by a post-hoc analysis (p=0.039). This study adds to the wealth of evidence around the positive benefit/risk profile of OXN PR in an Asian population.
Clinical trial identification
NCT00513656.
Editorial acknowledgement
Editorial assistance was provided by MedAcc Technology Co., Ltd.
Legal entity responsible for the study
Mundipharma (China) Pharmaceutical Co.LTD.
Funding
Mundipharma (China) Pharmaceutical Co.LTD.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
26P - Subcutaneous trastuzumab versus intravenous trastuzumab for treatment of patients with HER2-positive breast cancer: A time, motion and cost-benefit assessment in a day care oncology unit in China
Presenter: Bei Sun
Session: Poster Display
Resources:
Abstract
27P - The biological characteristics of HER2-low in TNBC using mRNA profiling and molecular subtypes
Presenter: Asako Tsuruga
Session: Poster Display
Resources:
Abstract
28P - One-week ultra-hypofractionated partial breast RT in early breast cancer: 3DCRT vs IMRT
Presenter: Nurilla Zaynutdinov
Session: Poster Display
Resources:
Abstract
30P - Stereotactic body radiotherapy using cyberknife versus interstitial brachytherapy in accelerated partial breast irradiation on left-sided breast: A comparison of preliminary clinical result and dosimetric characteristics
Presenter: Ting-Na Wei
Session: Poster Display
Resources:
Abstract
31P - Prognostic implication of breast edema on preoperative breast MRI in breast cancer
Presenter: Ki-tae Hwang
Session: Poster Display
Resources:
Abstract
32P - Efficacy of olanzapine in the prophylaxis of delayed chemotherapy-induced nausea and vomiting in breast cancer patients receiving dose-dense AC with a steroid-sparing regimen: A single-center pilot study
Presenter: Manami Tada
Session: Poster Display
Resources:
Abstract
34P - Social support as the mediator of the association between unmet needs and happiness among women with early breast cancer
Presenter: Nithiya Sinarajoo
Session: Poster Display
Resources:
Abstract
35P - Prospective study assessing the efficacy and safety of a scalp cooling device for the prevention of alopecia in breast cancer patients undergoing (neo)adjuvant chemotherapy
Presenter: Winnie Yeo
Session: Poster Display
Resources:
Abstract
37P - To excise or not to excise: Preventive management of early breast cancer in atypical ductal hyperplasia patients
Presenter: Clarisse Hing
Session: Poster Display
Resources:
Abstract
38P - Exploring prognostic factors in patients achieving PCR after neoadjuvant therapy for triple-negative breast cancer: A retrospective study based on SEER data
Presenter: Lv Wenjie
Session: Poster Display
Resources:
Abstract